TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel

Company Overview - TG Therapeutics, Inc. (NASDAQ: TGTX) is experiencing significant revenue growth driven by its FDA-approved drug BRIUMVI (ublituximab), which is used for treating patients with relapsing multiple sclerosis (RMS) [2]. Market Position - The company is part of the Biotech Analysis Central marketplace, which provides extensive resources for investors, including a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [2].